INBS · Intelligent Bio Solutions Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.06M | $896.8K | $1.11M | $741.1K | $907.6K | $906.0K | $764.1K | $823.8K | $796.1K | $356.7K |
| Cost of Revenue | $525.4K | $437.0K | $593.5K | $384.4K | $387.5K | $525.5K | $564.8K | $645.3K | $563.8K | $112.6K |
| Gross Profit | $535.4K | $459.7K | $518.3K | $223.1K | $341.4K | $346.8K | $199.2K | $178.5K | $232.3K | $244.0K |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $2.41M | $1.81M | $2.66M | $1.81M | $2.41M | $1.95M | $2.25M | $2.43M | $2.46M | $2.25M |
| Total Operating Expenses | $3.65M | $3.17M | $3.71M | $2.62M | $3.07M | $3.20M | $2.34M | $3.22M | $2.87M | $2.64M |
| D&A | $290.4K | $281.9K | $257.9K | $305.2K | $302.0K | $241.6K | $290.3K | $318.9K | $247.6K | $398.2K |
| Operating Income | ($2.95M) | ($2.64M) | ($3.00M) | ($2.26M) | ($2.55M) | ($2.73M) | ($1.99M) | ($2.95M) | ($2.53M) | ($2.13M) |
| Interest Expense | $4.2K | $56.2K | $3.9K | $32.5K | $42.7K | $37.4K | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.86M) | ($2.68M) | ($2.98M) | ($2.25M) | ($2.54M) | ($2.69M) | ($1.97M) | ($2.98M) | ($2.43M) | ($420.6K) |
| EPS - Basic | ($1.80) | ($2.82) | ($3.50) | ($5.00) | ($4.40) | ($7.00) | ($20.70) | ($14.30) | ($124.80) | ($55.20) |
| EPS - Diluted | ($1.80) | ($2.82) | ($3.50) | ($5.00) | ($4.40) | ($7.00) | ($20.70) | ($14.30) | ($124.80) | - |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.86M | $740.4K | $1.66M | $1.02M | $2.81M | $3.99M | $6.30M | $9.40M | $186.4K | $1.54M |
| Accounts Receivable | $878.4K | $456.7K | $717.8K | $594.6K | $511.0K | $578.6K | $429.7K | $431.6K | $567.5K | $293.9K |
| Inventory | $597.5K | $590.2K | $628.2K | $635.2K | $683.5K | $738.8K | $777.5K | $877.9K | $965.1K | $979.9K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $9.75M | $12.17M | $4.48M | $4.14M | $5.11M | $6.48M | $8.53M | $11.52M | $2.69M | $3.86M |
| Total Assets | $14.86M | $17.65M | $10.04M | $8.25M | $9.58M | $11.73M | $13.78M | $17.04M | $8.70M | $10.35M |
| Current Liabilities | $4.61M | $5.13M | $5.06M | $5.35M | $4.56M | $5.68M | $5.45M | $5.71M | $6.85M | $5.88M |
| Long-term Debt | - | - | - | - | - | - | $1.65M | - | - | - |
| Total Liabilities | $6.11M | $6.76M | $6.61M | $5.44M | $4.64M | $5.78M | $5.60M | $6.04M | $7.46M | $6.67M |
| Stockholders' Equity | $8.96M | $11.09M | $3.62M | $3.00M | $5.11M | $6.10M | $8.33M | $11.13M | $1.36M | $3.80M |
| Retained Earnings | ($71.06M) | ($68.19M) | ($65.52M) | ($62.53M) | ($59.44M) | ($54.65M) | ($51.96M) | ($49.18M) | ($44.23M) | ($41.81M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($2.85M) | - | - | ($2.39M) | - | - | ($1.31M) | - |
| Investing Cash Flow | - | - | ($70.4K) | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $3.56M | - | - | $42.5K | - | - | - | - |
| CapEx | - | - | $70.4K | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | ($2.92M) | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 50.5% | 51.3% | 46.6% | 30.1% | 37.6% | 38.3% | 26.1% | 21.7% | 29.2% | 68.4% |
| Operating margin | -277.8% | -293.9% | -269.8% | -305.5% | -281.3% | -300.8% | -260.6% | -358.6% | -317.3% | -597.4% |
| EBITDA margin | -250.4% | -262.5% | -246.6% | -264.4% | -248.0% | -274.1% | -222.6% | -319.8% | -286.2% | -485.8% |
| Net margin | -269.9% | -298.6% | -268.3% | -303.5% | -280.2% | -296.4% | -257.8% | -361.5% | -304.6% | -117.9% |
| Free cash flow margin | - | - | -262.4% | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.98 | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 227.6% | 201.7% | 239.2% | 244.1% | 265.3% | 215.1% | 293.9% | 294.5% | 308.6% | 629.5% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.3% | -15.2% | -29.7% | -27.3% | -26.5% | -22.9% | -14.3% | -17.5% | -27.9% | -4.1% |
| Return on equity | -31.9% | -24.1% | -82.4% | -75.1% | -49.7% | -44.0% | -23.6% | -26.7% | -178.9% | -11.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.11 | 2.37 | 0.89 | 0.77 | 1.12 | 1.14 | 1.57 | 2.02 | 0.39 | 0.66 |
| Quick ratio | 1.98 | 2.26 | 0.76 | 0.65 | 0.97 | 1.01 | 1.42 | 1.87 | 0.25 | 0.49 |
| Cash ratio | 1.49 | 0.14 | 0.33 | 0.19 | 0.62 | 0.70 | 1.16 | 1.65 | 0.03 | 0.26 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | 0.20 | - | - | - |
| Debt / Assets | - | - | - | - | - | - | 0.12 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -694.9x | -46.9x | -768.5x | -69.7x | -59.8x | -72.8x | - | - | - | - |
| Equity multiplier | 1.66 | 1.59 | 2.77 | 2.75 | 1.87 | 1.92 | 1.65 | 1.53 | 6.42 | 2.73 |
| Liabilities / Assets | 0.41 | 0.38 | 0.66 | 0.66 | 0.48 | 0.49 | 0.41 | 0.35 | 0.86 | 0.64 |
| Efficiency | ||||||||||
| Asset turnover | 0.07 | 0.05 | 0.11 | 0.09 | 0.09 | 0.08 | 0.06 | 0.05 | 0.09 | 0.03 |
| Inventory turnover | 0.88 | 0.74 | 0.94 | 0.61 | 0.57 | 0.71 | 0.73 | 0.74 | 0.58 | 0.11 |
| Days sales outstanding | 302d | 186d | 236d | 293d | 205d | 233d | 205d | 191d | 260d | 301d |
| Days inventory outstanding | 415d | 493d | 386d | 603d | 644d | 513d | 502d | 497d | 625d | 3175d |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.6x | 0.8x | 24.1x | 26.0x | 16.3x | 10.8x | 2.2x | 7.9x | 212.5x | - |
| P / S | 5.0x | 10.1x | 78.4x | 105.3x | 91.6x | 72.8x | 23.9x | 106.5x | 361.8x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 16.9% | 21.0% | 22.7% | -3.0% | 10.2% | 13.8% | 114.2% | 80.2% | 155.7% | 100.6% |
| Revenue CAGR (3y) | 32.4% | 36.0% | 52.9% | 60.9% | 67.7% | 153.8% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 56.8% | 106.1% | 49.4% | 12.0% | 91.3% | 49.3% | -18.4% | 440.1% | - | - |
| Operating income growth (YoY) | -15.4% | -16.4% | -10.1% | -13.7% | 13.6% | -7.9% | 6.6% | 54.9% | -107.4% | 38.5% |
| Net income growth (YoY) | -12.5% | -19.0% | -11.1% | -14.2% | 14.6% | -10.7% | -368.3% | 53.1% | -100.7% | 87.8% |
| EPS growth (YoY) | 59.1% | 43.6% | 50.0% | 75.8% | 69.2% | 94.4% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 75.3% | 270.2% | -40.7% | -64.0% | -54.1% | 350.3% | 119.3% | 84.7% | -74.3% | -42.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Product / service
$3.05M totalSales Of Goods Cartidges$1.76M · 57.7%
Sales Of Goods Readers$711.7K · 23.3%
Other Sales$578.6K · 19.0%
Geographic
$3.05M totalGB$2.87M · 94.0%
Other Country$132.7K · 4.3%
Asia Pacific$29.2K · 1.0%
Americas$22.6K · 0.7%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing INTELLIGENT BIO SOLUTIONS INC. against the 5 most active filers in the same SIC group.